What technology area does this patent fall under?

Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.

When was this patent published?

Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.

What related patents are in patentsdb?

We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).

Optimized FC variants and methods for their generation

US9353187B2 · US · B2

Patent metadata
Field	Value
Publication number	US-9353187-B2
Application number	US-201313773485-A
Country	US
Kind code	B2
Filing date	Feb 21, 2013
Priority date	Sep 27, 2002
Publication date	May 31, 2016
Grant date	May 31, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

Title
What the patent document calls the invention.
Abstract
A short plain-language summary of the technical disclosure.
Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
Key dates
Filing, priority, publication, and grant dates set the timeline.
First independent claim
The legal scope of protection — read this for what is actually claimed.
CPC / IPC classifications
Technology tags used to group this patent with similar filings.
Citations and related patents
Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.

First claim

Opening claim text (preview).

We claim: 1. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 239D substitution in the Fc region, wherein numbering is according to the EU index. 2. A method of mediating antibody-dependent cell-mediated cytotoxicity (ADCC) in a human comprising administering to a human a composition comprising a variant antibody of a parent antibody which variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of human peripheral blood mononuclear cells more effectively than the parent antibody, wherein said variant comprises a 239E substitution in the Fc region, wherein numbering is according to the EU index. 3. A method according to claim 1 or 2 wherein said variant antibody is a monoclonal antibody. 4. A method according to claim 1 or 2 wherein said variant antibody is a humanized antibody. 5. A method according to claim 1 or 2 wherein said variant antibody is a chimeric antibody. 6. A method according to claim 1 or 2 wherein said antibody binds to CD19. 7. A method according to claim 1 or 2 wherein said antibody binds to IgE. 8. A method according to claim 1 or 2 wherein said parent antibody is a human IgG1. 9. A method according to claim 1 or 2 wherein said variant antibody binds to a target antigen selected from the group consisting of CD20, CD30, CD33, CD37, CD38 and CD3.

Assignees

Xencor Inc

Inventors

Classifications

A61P37/02
Immunomodulators · CPC title
A61P35/00
Antineoplastic agents · CPC title
A61P37/04
Immunostimulants · CPC title
C07K2317/21
from primates, e.g. man · CPC title
A61K39/395
Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

Patent family

Related publications grouped by family.

View patent family 33437072

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9353187B2 cover?: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Who is the assignee on this patent?: Xencor Inc
What technology area does this patent fall under?: Primary CPC classification C07K16/32. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?: Publication date Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?: We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).